Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25834408 | 0.93 | HRH3 (0.39) | HRH3 | |
| SCHEMBL21660306 | 0.92 | HRH3 (0.40) | HRH3CCR2KCNH2 | |
| SCHEMBL22893242 | 0.89 | HRH3 (0.47) | HRH3CCR2KCNH2 | |
| SCHEMBL26032818 | 0.89 | HRH3 (0.38) | HRH3 | |
| SCHEMBL24022579 | 0.87 | HRH3 (0.38) | HRH3CCR2KCNH2 | |
| SCHEMBL20665602 | 0.87 | HRH3 (0.36) | HRH3 | |
| SCHEMBL24700866 | 0.86 | HRH3 (0.47) | HRH3CCR2KCNH2 | |
| SCHEMBL26194411 | 0.84 | HRH3 (0.46) | HRH3CCR2KCNH2 | |
| SCHEMBL19960851 | 0.84 | HRH3 (0.33) | HRH3CCR2KCNH2 | |
| SCHEMBL22011389 | 0.83 | CCR2 (0.33) | HRH3CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10363257-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-07-30 | — | — | US | disclosed |
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-01-01 | — | — | US | disclosed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9663520-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10363257-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | HRH3 829/4885CCR2 832/4885KCNH2 3623/4885 |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | HRH3 998/4885CCR2 807/4885KCNH2 4199/4885 |
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | BRD4, BRD3, BRD2 | HRH3 923/4885CCR2 759/4885KCNH2 3985/4885 |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | HRH3 853/4885CCR2 593/4885KCNH2 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.